MSI-H Experience Delivers Another Exciting Breakthrough in Immuno-Oncology

Gina Columbus @ginacolumbusonc
Published: Friday, Nov 10, 2017

Regarding next-generation sequencing panels, Le emphasized the importance of adding MSI testing for patients with solid tumors as it can assist physicians in providing quicker treatment decisions.

“If someone has high tumor mutational burden, you might consider that they have MSI- instability, although that’s not always the case,” Le said. “While [MSI-high tumors are] rare, the PD-1 therapy can have a profound treatment effect.”

For the future, Lee acknowledged that researchers are further refining immunotherapy as a standard option for patients with high tumor mutational burden, specifically MSI-high tumors. Additional areas of research include studying PD-1 inhibition in earlier stages and lines of therapy, she concluded.


  1. US Food and Drug Administration. FDA approves first cancer treatment for any solid tumor with a specific genetic feature. c. Updated May 23, 2017. Accessed November 9, 2017.
  2. Overman MJ, Lonardi S, Leone F, et al. Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: update from CheckMate 142. J Clin Oncol. 2017;35 (suppl 4S; abstract 519).

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesJan 30, 20182.0
Medical Crossfire®: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future DirectionJan 30, 20181.5
Publication Bottom Border
Border Publication